Louis Garguilo

ARTICLES BY LOUIS

  • You Decide: Technologies Impacting Drug Development And Manufacturing
    You Decide: Technologies Impacting Drug Development And Manufacturing

    Quickly: What three technologies impact your drug development and manufacturing? How do those technologies impact your outsourcing partners, processes, and decisions? Thanks for joining today’s flash mind exercise. You’ve also joined executives on the Outsourced Pharma Editorial Advisory Board who did the same. Let’s compare.

  • New Report Helps Forecast Next 5 Years Of Outsourcing
    New Report Helps Forecast Next 5 Years Of Outsourcing

    Discerning growth opportunities (or business contractions) in the drug development and manufacturing outsourcing space is a challenging exercise. Among other things, it requires reading between the lines of various industry reports concentrating otherwise, for example on comparing commercial product sales and R&D pipelines. An “otherwise” focused report worth our attention is the EvaluatePharma World Preview 2017, Outlook to 2022

  • Channeling Socrates With The FDA On Innovative Technologies
    Channeling Socrates With The FDA On Innovative Technologies

    Paraphrasing Henry Hoppe of Xenetic Bioscience, companies on the bleeding edge of innovative technology in drug development and manufacturing should treat visits to the FDA more like Socratic dialogues than stressful duels. Mark Butchko, who’s charted over a decade with Lilly, advises holding some of those dialogues during “pre-operational visits,” or POVs.

  • New Board Members: Co-Creating, Energized, And Positively Provocative
    New Board Members: Co-Creating, Energized, And Positively Provocative

    It’s halftime on 2017. Summer has officially arrived. Can you believe it? A perfect time to … add veteran industry professionals to our organization. Outsourced Pharma is pleased to announce three new Editorial Advisory Board members, from Merck, Eli Lilly, and Tunnell Consulting. Read what they have to say about our industry to this point, and our future.

  • The Less And More In Biogen’s Supply Chain
    The Less And More In Biogen’s Supply Chain

    Consolidate by (a) providing trusted partners more opportunity, and (b) initiating fewer new relationships except where technology-critical. Also: look for innovation at experienced providers, while the less inured work to gain your trust. So say three Biogen executives. Here are the details.

  • Continuous Manufacturing In The Mediterranean Sea
    Continuous Manufacturing In The Mediterranean Sea

    Leaders from organizations such as Lilly, Janssen, the EMA, Rutgers University and the University of Malta, gathered in a Mediterranean setting to dive into the waves of continuous manufacturing adoption and regulatory challenges for global drug development and production.

  • Japan And The Art Of Supply-Chain Specialization
    Japan And The Art Of Supply-Chain Specialization

    So you say you’re a specialist. And that’s probably a good thing. But consider this paradox: The best “specialists” are also solid “generalists.” I’m reminded of this contrarian concept by a recent visit to Japan, where I originally learned it, and the ongoing debate at Outsourced Pharma conferences regarding partnerships in the external supply chain.   

  • What Is Supply Chain Capacity In 2017?
    What Is Supply Chain Capacity In 2017?

    “Capacity” for outsourcing development and manufacturing has mostly been defined by a strict calculation of how much material a facility (or facilities) can output over a period of time. Executives from companies like MedImmune and Merck tell us why, unfortunately, that definition doesn’t work anymore.

  • Instant Innovation In The Supply Chain
    Instant Innovation In The Supply Chain

    In our second part on supply chain innovation, executives at Biogen and Merck discuss the drug industry’s engagement with “instant innovation,” and a bottom up approach to cultural change.

  • Risk And Small “i” Innovation In Pharma Outsourcing
    Risk And Small “i” Innovation In Pharma Outsourcing

    Innovation brings risk. Pharma is risk averse. Therefore, we have less innovation than in other industries. Most likely you’ve heard it all before. But is it valid? We talk to executives from Biogen, Merck, and Sanofi Biologics to find out. 

Louis Garguilo

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.